01Year-one trial numbers, not forum folklore
Three 12-month controlled trials for Propecia (finasteride 1 mg) enrolled 945 men on drug and 934 on placebo. Drug-related sexual adverse experiences in year one sit in a small table, not in a Reddit collage.
Decreased libido 1.8% versus 1.3% placebo. Erectile dysfunction 1.3% versus 0.7%. Ejaculation disorder 1.2% versus 0.7%, including decreased ejaculate volume 0.8% versus 0.4%. Discontinuation for drug-related sexual AE: 1.2% versus 0.9%.
Integrated analysis: 36 of 945 men (3.8%) reported one or more of those sexual experiences versus 20 of 934 (2.1%) on placebo. Resolution occurred in men who stopped and in most who continued.
Finpecia 1 mg is still finasteride. Export branding does not delete Table 1. Read the INN pulse if you came here from a name fight.
Discontinuation for drug-related sexual AE was 1.2% versus 0.9% placebo. That gap is small. An individual man can still be in it. Elective therapy can end without a stair.
| Year-1 drug-related sexual AE | Finasteride 1 mg (n=945) | Placebo (n=934) |
|---|---|---|
| Decreased libido | 1.8% | 1.3% |
| Erectile dysfunction | 1.3% | 0.7% |
| Ejaculation disorder (dec. volume) | 1.2% (0.8%) | 0.7% (0.4%) |
| Stop for sexual AE | 1.2% | 0.9% |
02Decreased libido at 1.8 percent
One point eight percent is not 'everyone.' It is also not zero. Elective hair therapy should be offered with that sentence, not with a shrug.
A sexual function questionnaire in vertex trials found statistically significant differences favoring placebo at month 12 in sexual interest, erections, and perception of sexual problems. Overall satisfaction with sex life did not differ significantly in that instrument.
By year five, the incidence of each listed sexual AE fell to 0.3% or less among those still on Propecia in the extension data the label cites. New reports decreased with time. That does not erase an individual man who feels worse at month two.
Nocebo from horror threads is real. So is a man who wants to stop at the first change. Both can be true. This desk will not mock either.
03Semen exposure and pregnancy
Crushed-tablet handling is the sharpest household risk. Semen exposure counselling belongs with the clinician who wrote the script.
If pregnancy is the near-term goal, some men pause finasteride before trying. That pause is a fertility-clinic decision, not a pulse order.
Blood donation deferral continues until the labeled wait after the last dose. Do not skip the donor questionnaire.
Sexual AE plus a new PDE5 habit needs a nitrate check. See the finasteride vault and the sildenafil vault before you stack.
04New sexual reports fell by year five
Propecia extension language says the incidence of each listed sexual AE decreased to 0.3% or less by the fifth year among men still on drug. New reports also declined with time.
That sentence comforts population readers. It does not erase a man who feels worse at week six. Individual exit remains valid. No taper.
There is no evidence in the 5 mg BPH data that sexual AE keep climbing with duration; new reports decreased there too. Do not use that as a dare to ignore a current change.
Questionnaire data at month 12 still found domain differences versus placebo in interest, erections, and perception of problems, without a significant gap in overall sex-life satisfaction. Both facts can sit on one chip.
Qivana will not invent a 'year-five safe' marketing percent. We will not invent a Finpecia dollar that pretends AE were priced in.
05Post-stop reports sit on the label
US labeling added post-marketing language that sexual dysfunction, including libido and ejaculation disorders, has been reported to persist after discontinuation. Quality of evidence for a named 'syndrome' is debated; the counselling duty is not.
FDA reviewed post-marketing sexual reports and trial data. Most reported sexual effects in that review returned toward baseline within months after stop, but the agency still wanted patients told.
Infertility and semen-quality reports that improved after stop also entered labeling. They are uncommon relative to the hair indication. Men planning conception should say so before they start.
Qivana will not invent a persistence percentage the label does not give. We will not invent a Finpecia price that 'includes a guarantee.' There is no such guarantee.
06Breast change is uncommon, not imaginary
Gynecomastia and tenderness appear in finasteride AE lists. They are less frequent than the year-one sexual table and still worth a sentence before consent.
Unilateral hard masses need examination. Do not assume 'it's the Finpecia' and ignore a lump.
PDE5 tablets such as sildenafil do not treat finasteride-related desire change. They may help erection if the clinician agrees and nitrates are absent. Stacking unmarked export ED tablets on a grey Finpecia carton is a bad shop-pipe move.
Partner distress is part of the review. A man who says 'fine' while the relationship is not fine still needs a documented check-in.
07Sildenafil does not restore wanting
A clinician may add a PDE5 tablet if erection is the main change and nitrates are absent. Desire change is a different row. Fildena from the same grey banner as Finpecia is a bad stack.
Read the sildenafil vault before anyone writes that add-on. Once-daily frequency and the nitrate ban still apply.
Ejaculate-volume change listed at 0.8% versus 0.4% placebo is usually volume, not a fertility emergency by itself. Conception plans still need a spoken sentence.
Breast mass is imaging. Rash with lip swelling is a stop. Neither waits for month-three hair photos.
Elective exit remains: hold 1 mg, call, no taper. Hair will drift back. That cost should be named before tablet one, not after a forum spiral.
08Plan a spoken check at month three
Hair photos and a sex-and-mood note can share one calendar date. Silent refills skip both.
Year-five population drops in new sexual AE do not erase a week-six crash. Exit needs no taper.
Depression or suicidal talk is a stop-and-call row, not a 'push through for density' row. Emergency lines first if you are in crisis.
Breast lumps need examination. Unilateral hard masses are imaging, not a forum shrug.
Conception plans should be spoken before tablet one. Semen-quality reports after stop exist. This desk will not invent a persistence percent.
09No taper to quit finasteride
Unlike clonidine or cortisol tapers, 1 mg finasteride can stop without a stair. Hair density will drift back toward the pre-drug path over months.
Do not double the next dose after a week of missed tablets. Restart daily 1 mg if you and the clinician still want the indication.
Women must not start this tablet for male-pattern protocols written for men. Handling crushed tablets remains a pregnancy issue after you quit until the household is clear.
Table 1 on this AE chip was sealed 21 August 2026. Mail a wrong percent to [email protected]. Do not mail a symptom for personal triage.
10Write libido and mood before tablet one
Elective hair therapy goes cleaner if you jot desire, morning erections, ejaculate volume, and mood for two weeks before the first 1 mg. Forum memory is a poor baseline.
A three-month photo set and a three-month sex note can be compared on the same calendar. Hair gain that costs a relationship still needs a spoken decision, not a silent push.
Partners who will handle laundry or pill boxes need the crushed-tablet warning in plain words before day one, not after a broken tablet on the floor.
Men with prior depression should have a named check-in, not a 'see you in a year' refill. Post-marketing mood reports are uncommon and still a stop-and-call row.
If you already started without notes, start the log now. Late data is better than no data when you decide whether to continue Finpecia or a local generic.
11Depression is a counseling item
Post-marketing reports include depression and, rarely, suicidal ideation. That is a stop-and-call row, not a 'push through for hair' row.
Men with prior mood disorder need a clearer pre-start talk than a shop FAQ. Hair loss itself lowers mood. The tablet can still be a second hit.
Breast tenderness or enlargement is uncommon (label ranges for breast events sit under 2% in some 5-alpha-reductase summaries). A new breast mass is imaging, not a forum shrug.
Rash and hypersensitivity are uncommon. Stop for swelling of lips or tongue. That is not a sexual AE and does not wait for month three photos.
12Elective hair medicine needs an exit plan
Year-one percents are small and statistically real versus placebo. Persistence after stop is reported. Price theater does not buy silence.
Start only if the hair goal beats your anxiety budget. Baseline notes, a three-month check, and a clean stop if needed.
PDE5 can help erection if a clinician agrees and nitrates are absent. It does not restore desire. Do not stack unmarked Fildena from the same banner.